The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.
NPJ Genom Med
Springer Science and Business Media LLC
MetadataShow full item record
Lago, S. G., & Bahn, S. (2022). The druggable schizophrenia genome: from repurposing opportunities to unexplored drug targets.. NPJ Genom Med, 7 (1) https://doi.org/10.1038/s41525-022-00290-4
Funder: Stanley Medical Research Institute (SMRI); doi: https://doi.org/10.13039/100007123
There have been no new drugs for the treatment of schizophrenia in several decades and treatment resistance represents a major unmet clinical need. The drugs that exist are based on serendipitous clinical observations rather than an evidence-based understanding of disease pathophysiology. In the present review, we address these bottlenecks by integrating common, rare, and expression-related schizophrenia risk genes with knowledge of the druggability of the human genome as a whole. We highlight novel drug repurposing opportunities, clinical trial candidates which are supported by genetic evidence, and unexplored therapeutic opportunities in the lesser-known regions of the schizophrenia genome. By identifying translational gaps and opportunities across the schizophrenia disease space, we discuss a framework for translating increasingly well-powered genetic association studies into personalized treatments for schizophrenia and initiating the vital task of characterizing clinically relevant drug targets in underexplored regions of the human genome.
Review Article, /631/154/555, /692/699/476/1799, /631/154/433, /631/208/726, review-article
External DOI: https://doi.org/10.1038/s41525-022-00290-4
This record's URL: https://www.repository.cam.ac.uk/handle/1810/335562